Please login to the form below
Exondys 51
This page shows the latest Exondys 51 news and features for those working in and with pharma, biotech and healthcare.
CHMP backs Spark’s Luxturna, but rejects Sarepta again
Eteplirsen was approved in the US as Exondys 51 in 2016, although the decision came after FDA reviewers recommended that the drug be rejected as the evidence for its benefits was ... which there was no meaningful difference between Exondys and placebo in
Latest news
-
Pfizer abandons antibody for Duchenne
News of the setback spurred modest gains in the share price of Sarepta, which sells exon-skipping therapy Exondys 51 (eteplirsen) in the US and Europe, as well as PTC Therapeutics
-
Daily Brief: Sarepta deepens gene therapy investment, NICE changes mind on Besponsa, Digital Medicine company Akili raises $13m
Sarepta has made its name by launching the first ever FDA approved treatment for Duchenne muscular dystrophy, Exondys 51, and is now looking to expand its pipeline into other rare disease ... Sarepta has also just announced rising sales of Exondys 51,
-
Mallinckrodt doses first patient in muscular dystrophy trial
For now, the only approved therapies are Sarepta’s exon-skipping therapy Exondys 51 (eteplirsen), which has some controversy over its efficacy, PTC’s Translarna (ataluren), which is available in Europe
-
Summit plunges after Duchenne disappointment
Sarepta's investment in the field has been possible thanks to the FDA’s approval of the first US-approved Duchenne drug, Exondys 51, in 2016, despite controversies over its efficacy. ... The field is marked by the curiosity of the EMA having approved
-
Sarepta soars on positive Duchenne data
it’s already a player in DMD therapy with its exon-skipping Exondys 51 (eteplirsen) therapy – approved in the US but not the Europe – but that drug is only suitable for
More from news
Approximately 3 fully matching, plus 9 partially matching documents found.
Latest Intelligence
-
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Alnylam can take heart in exceptions, however, such as Sarepta, with its Duchenne treatment Exondys 51, and hope it too can buck this trend.
-
Europe vs the US: New drug product approvals
Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US
-
Deal Watch February 2017
Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
- Senior Account Managers - Oxfordshire
-
Attractive salary and benefits package offered
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Consumer Health Account Director
-
Circa £60, 000 Gym and More
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Associate Medical Director
-
Highly Competitive
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Senior Medical Writer (Remote Working)
-
Competitive Salary Offered
- Director, Market Access / HEOR - North-West
-
Negotiable
-
Account Director
-
£48, 000 - £60, 000
-
Medical/ Scientific Director
-
Salary TBC
- Senior Systematic Review Analyst - Oxford
-
Negotiable
Subscribe to our email news alerts
- The handover: Pfizer reshapes itself for a new era
- AbbVie sues NHS England over hep C procurement
- GSK among businesses wooed as Brexit reckoning nears
- BioMarin eyes 2019 FDA filing for haemophilia A gene therapy
- The handover: Pfizer reshapes itself for a new era
- Novartis: pipeline will generate 60 filings in three years
- Artificial Intelligence In Healthcare Market to Witness Exponential Growth by 2027
- Breathing Exercise Devices Market Intelligence Report Offers Growth Prospects
- Micro-CT Scanners Market 10-Year Market Forecast and Trends Analysis Research Report
- Next Generation Infusion Pump Market Healthy Pace throughout the Forecast during 2017 – 2027
- Wireless Brain Sensors Market Intelligence Report Offers Growth Prospects
- MRI Guided Neurosurgical Ablation Market is Projected to Expand at a CAGR of 4.9% During the Forecast Period 2018–2028 and Reach US$ 216.3 Mn By the End of 2028
PMHub
Wordbird
Wordbird is a healthcare communications agency with creative, compelling copy at its heart....
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
